94 results
8-K
EX-99.1
FGEN
FibroGen Inc
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
ongoing clinical investigation in LAPC and metastatic pancreatic cancer. Pamrevlumab is an investigational drug and not approved for marketing by any
8-K
EX-99.1
8m3fw80 c0etb1fsqwb
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
EX-99.1
vxfjhjvbd dczw1jm7
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
etzvte4 v97az9p
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
ugjonk k6wqtuw0rg1
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
au4ta79lrm j8s
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
cadhwgxh
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
y1xhqly2 8kh
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm